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ABSTRAcT
Objectives: The aim was to present an interdisciplinary Guideline of the Urogynecology Section of the Polish Society of 
Gynecologists and Obstetricians (PSGO) for the use of urodynamics (UDS) in the diagnostic process of patients with lower 
urinary tract symptoms (LUTS) based on the available literature, expert knowledge, and everyday practice. 
Material and methods: A review of the literature concerning the use of UDS in women, including current international 
guidelines and earlier recommendations of the PSGO Urogynecology Section, was conducted. 
Results: Urodynamic testing allows to make the urodynamic diagnosis which, nevertheless, remains to be the preliminary 
diagnosis. Medical history, physical examination, and detailed analysis of the previous test results (laboratory, imaging, 
endoscopic) need to be taken into consideration before making the final diagnosis. Urodynamic testing before surgical 
treatment of SUI is allowable, but the decision remains at the discretion of the physician. Urodynamic testing is not neces-
sary before primary surgical treatment of uncomplicated SUI, but it has been demonstrated to optimize the therapeutic 
methods in complicated SUI. The significance of UDS in the diagnostic process of patients with overactive bladder symptoms, 
voiding dysfunction, and bladder outlet obstruction was discussed. 
conclusions: Urodynamic testing is a vital element of the urogynecological diagnostic process. The scope of UDS should 
reflect the individual needs and symptoms of each patient and be based on the current guidelines, expert knowledge and 
experience of the physician, indications, and eligibility, as well as additional test results of the affected patients. Due to 
formal and legal requirements, PSGO, in this Guideline, wishes to emphasize the need for an individualized approach to 
both, test performance and result interpretation.
Key words: urodynamics, stress urinary incontinence, overactive bladder, voiding dysfunction, bladder outlet obstruction, 
guidelines
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INTRODUcTION
Urodynamics (UDS) is a collective term used to describe 
tests which evaluate the function of the lower urinary tract, 
including bladder and urethral pressure, urethral flow rate, 
and electromyographic measurements. 
UDS includes uroflowmetry, cystometry with stress 
tests (cough test and Valsalva maneuver) — with or with-
out pressure-flow test, resting and cough urethral pressure 
profilometry, electromyography, and video-urodynamics 
[1, 2]. These functional tests allow for the assessment of 
the bladder contractile function, urethral resistance and 
continence. The main indication for urodynamic testing 
is a specific UDS question. The choice of the urodynamic 
components depends on the clinical status of the patient 
and the experience of the physician.
Based on UDS, urodynamic diagnoses are made, which 
may not be equivalent to the clinical diagnosis, as they 
only determine the state of the urinary tract recorded in 
a given measurement. Importantly, any of the urodynamic 
tests may generate false positive and false negative results 
and the tests are characterized by a certain variability of 
observation in recognizing different conditions. Therefore, 
urodynamic test results should not be perceived as the final 
diagnosis. Data from medical history, physical examination, 
and earlier test results (e.g., laboratory, imaging and endo-
scopic), are necessary to interpret the results.
Objectives
The aim was to develop a Guideline on the use of uro-
dynamic testing in the diagnostic process of patients with 
lower urinary tract symptoms (LUTS), based on the available 
literature reports, expert knowledge, and everyday practice.
MATERIAl AND METhODS 
The literature, including current international guide-
lines, was reviewed for the following content: the use of 
UDS in the diagnostic process, patient eligibility for treat-
ment, and the efficacy of stress urinary incontinence (SUI), 
overactive bladder/detrusor overactivity, voiding dysfunc-
tion, and bladder outlet obstruction therapies. Data quality, 
risk-to-benefit ratio, availability of the resources in Poland, 
and the consensus of the experts were analyzed for all guide-
lines. Recommendations with uncertain risk-to-benefit ra-
tio and discrepancies between research results and expert 
opinions were excluded.
REvIEW Of ThE lITERATURE,  
INclUDING GUIDElINES
UDS in patients with SUI
The significance of UDS in the process of determining 
patient eligibility for the surgical treatment of SUI was evalu-
ated in the VALUE and VUSIS I and II randomized clinical 
trials. The effects of surgical treatment in patients with and 
without pre-surgery UDS were compared [3–5]. After these 
results were published, the number of urodynamic tests 
decreased. The VALUE trial found no correlation between 
UDS and higher efficacy of the surgical treatment of uncom-
plicated SUI, as defined by the American Urogynecologic 
Society (AUGS) and the American College of Obstetricians 
and Gynecologists (ACOG). However, many experts have 
raised concerns about the design of these two RCTs and 
their subsequent interpretation. The effects were evaluated 
solely with questionnaires and the cough test. The surger-
ies were mostly performed by physicians in training, not 
by experts. Surgery types and eligibility criteria were not 
described [3]. Similar conclusions were reported after the 
VUSIS I trial, which had only 59 participants. In the VUSIS 
II trial, with 109 patients, no evidence was found of reduced 
efficacy of mid-urethral sling implantation in patients with 
SUI who had not undergone UDS before surgery. The sam-
ple size in both VUSIS trials was relatively small. Also, there 
were significant inter-center differences in terms of indica-
tions, planning and techniques for SUI management, so 
the effects of UDS on the surgical outcome varied to some 
extent. Notably, the VALUE trial included only women with 
uncomplicated SUI [4–6].
Urodynamic testing is not necessary before the primary 
surgical repair of uncomplicated SUI if the symptoms and 
normal urethral mobility were confirmed by medical history 
and if the cough test was positive. The following will need 
to be excluded: clinically significant vaginal and uterine 
prolapse during the Valsalva maneuver, recurrent urinary 
tract infections, and post-void urine retention [7–9]. Ac-
cording to the AUGS criteria, patients with uncomplicated 
SUI have a history of involuntary urine leakage on effort 
and coughing but no evidence of recurrent urinary tract 
infections, hematuria, incomplete emptying, chronic uri-
nary retention, and absence of voiding symptoms such as 
hesitancy, slow stream, intermittency, and straining to void. 
These patients have no prior anti-incontinence surgery or 
extensive pelvic surgery, and no illnesses which might affect 
the urinary tract function, e.g., neurologic diseases. Their 
physical examination shows no signs of post-void residual 
(PVR) volume of > 100 mL or POP beyond the hymen. These 
patients also have normal urethral mobility and absence of 
urethral abnormality [7, 8, 10, 11]. 
Among women with SUI, uncomplicated SUI is diag-
nosed in 5–36% of the cases [12–15]. In the VALUE trial, 
66% of the patients were excluded from the study for not 
meeting the eligibility criteria for uncomplicated SUI [3].
UDS in patients with UI, especially with complicated 
SUI, has been proven to optimize the therapeutic decision 
[16–21]. A multicenter trial, which included 2053 women, 
demonstrated that urodynamic testing led to the reevalua-
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tion and change of the original UI diagnosis in 74.6% of the 
patients with complicated and 40% with uncomplicated 
SUI [18]. Management alterations based on the UDS results 
occurred in 62% of the patients, and the sling surgery was 
abandoned in 15% of the cases [18]. UDS found features 
of detrusor overactivity [22] and functional bladder outlet 
obstruction in as many as 20% of the patients with uncom-
plicated SUI diagnosed based on medical history [13, 19]. 
Voiding dysfunction, which is associated with higher risk of 
sling surgery failure [23], has been demonstrated in 10% of 
the women with uncomplicated SUI [3]. 
The authors of this Guideline believe that urodynamic 
testing is not necessary before the surgical repair of uncom-
plicated SUI if the findings do not affect the type of the pro-
cedure and if the probability of a successful outcome is high 
[6]. Urodynamic testing is allowable in all patients before 
surgical repair of SUI [24–26]. The decision is subjective and 
based either on the experience of the physician or on the 
formal and legal requirements. Data from the randomized 
trials on the possibility of omitting UDS before elective surgi-
cal repair of SUI apply only to patients with uncomplicated 
SUI. Pre-operative urodynamic testing may be beneficial in 
women with complicated SUI as it allows to determine the 
risk for failure of the standard surgical treatment [7, 16–19]. 
Patients with uncertain UI type or those with the suspicion 
of overflow incontinence may also benefit from UDS before 
surgery [24]. 
In various urogynecological centers, the diagnostics of 
the intrinsic sphincter deficiency (ISD) is performed during 
UDS. There are no standard diagnostic procedures for ISD. 
Bladder pressure at which leakage occurs (VLPP, Valsalva 
Leak Point Pressure) is measured during cystometry, during 
the Valsalva maneuver. The maximal urethral closure pres-
sure (MUCP) is tested during urethral pressure profilometry 
(UPP) at rest [4, 27].
UDS in the evaluation and conservative 
treatment of the overactive bladder syndrome
Overactive bladder syndrome (OAB) is a symptom com-
plex associated with the lower urinary tract, i.e., urgency, fre-
quency, nocturia and/or urgency urinary incontinence. OAB 
is not a separate disease entity and, as such, is not registered 
in the international classification of diseases. Nevertheless, 
the term ‘overactive bladder syndrome’ is commonly used by 
physicians in medical documentation and in the literature, 
in accordance with the International Continence Society 
(ICS) definition [28], and it is also a reimbursement criterion 
for certain drugs in Poland. OAB is suggestive of, but not 
consistent with, detrusor overactivity. The diagnosis can be 
made after ruling out urinary tract infections, urolithiasis 
and urinary tract cancers, bladder outlet obstruction, and 
diseases of the nervous system. Thorough medical history 
should be taken, and urinalysis should be performed in the 
diagnostic process due to urgency and frequency [29, 30]. 
The decision to include post-void residual volume, urine 
culture, or micturition diary into the evaluation should be 
left to the discretion of the physician. Contrary to some 
opinions [29, 30], the authors of this Guideline believe that 
an ultrasound examination, combined with the evaluation 
of post-void residual volume, should be incorporated into 
the initial diagnostic process to exclude other causes of the 
symptoms. However, ultrasound parameters of the bladder 
such as wall thickness are not useful for the diagnosis of 
detrusor overactivity [2]. Our recommendation is based, 
among others, on the following: 1) availability of ultrasound 
devices in gynecological and urological offices, 2) age-de-
pendent increase in the risk for bladder tumor (mean 0.5%), 
3) vesical calculi as the possible cause of such symptoms, 
4) non-invasive nature of ultrasound testing [31, 32]. 
The role of UDS in OAB diagnosis is limited to specialist 
management in selected, complicated cases. Urodynamic 
testing is not recommended at the initial stages of OAB diag-
nosis [30], or as part of the qualification for pharmacological 
treatment due to insufficient sensitivity and specificity of the 
tests regarding idiopathic detrusor overactivity. Only about 
half of the patients with non-neurogenic detrusor overac-
tivity diagnosed with UDS experience bothersome urinary 
urgency [33]. At the same time, only 50–60% of women with 
typical OAB symptoms present with uncontrolled detrusor 
contractions recorded during the filling phase of cystometry 
[34, 35]. Other arguments against routine UDS in patients 
with OAB include low inter-observer reproducibility of the 
result [36], and no evidence of a relationship between the 
prevalence or severity of detrusor overactivity symptoms 
and treatment effects [20, 37]. 
UDS may play a role in the diagnostic process after all 
pharmacological treatment options for OAB have been ex-
hausted, in cases of OAB concomitant with other pelvic floor 
disorders for example: urinary incontinence, voiding dys-
function, pelvic organ prolapse, pain, or with inconclusive 
medical history and/or symptoms. It is not possible to list the 
conditions when urodynamic testing is indispensable. The 
decision to perform urodynamic tests remains subjective 
and may reflect the experience of the physician or may be 
based on the formal and legal requirements. 
The role of UDS before invasive OAB treatment 
UDS before BTX injections 
Botulinum toxin (BTX) injection therapy has been regis-
tered and recognized as an effective management of drug 
resistant OAB. The main risks associated with the procedure 
include voiding disorders, urinary retention with the need 
for self-catheterization, and urinary tract infections. Howev-
er, in the group of women receiving 100 IU of onabotulinum-
233
Artur Rogowski et al., The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians Guideline
www. journals.viamedica.pl/ginekologia_polska
toxin A, these complications have been reported to be rare 
(≤ 5%) [38]. The diagnosis of detrusor overactivity using UDS 
has not been proven to be related with higher efficacy of this 
therapy. Therefore, patients with OAB symptoms, without 
detrusor contractions during the filling phase, are as likely 
to benefit from BTX therapy as those with confirmed over-
activity [39]. Other urodynamic observations, e.g., detrusor 
underactivity and bladder outlet obstruction, may increase 
the risk for voiding dysfunction after surgery [40]. Still, it is 
not an indication for routine UDS before BTX therapy, also 
within the current clinical trial framework [41]. The Ital-
ian expert panel concluded that UDS should be obligatory 
in patients with neurogenic detrusor overactivity or with 
a suspicion of voiding dysfunction. Otherwise, urodynamic 
testing is not necessary. They also recommended to perform 
at least a single uroflowmetry with PVR volume evaluation 
to exclude voiding dysfunction before BTX therapy [42]. 
The authors of this Guideline believe that an ultrasound 
test, with simultaneous evaluation of the post-void residual 
volume, should be considered to rule out other sources of 
the symptoms.
UDS before sacral neuromodulation
Sacral neuromodulation (SNM) is an invasive treat-
ment of therapy resistant detrusor overactivity, voiding 
dysfunction unrelated to bladder outlet obstruction, and 
fecal incontinence. It has also been experimentally used 
to treat neurogenic dysfunctions and chronic pelvic pain 
syndrome. Percutaneous sacral nerve stimulation, routinely 
performed before the final implantation, is the only predic-
tor of therapy efficacy. No relation has been found between 
detrusor overactivity recorded in UDS and the efficacy of 
sacral neuromodulation [43]. Although in some medical 
centers urodynamic testing is included in the eligibility 
process, it is not standard management and no cases of 
better treatment outcomes of typical, uncomplicated, resist-
ant to pharmacotherapy OAB after routine UDS have been 
reported [44]. In their statement, the ICS expert panel con-
cluded that urodynamic testing was more justified during 
the eligibility process in patients with neurogenic dysfunc-
tion, comorbid SUI, or voiding dysfunction, as well as after 
prior procedures affecting the function of the lower urinary 
tract, e.g., implantation of a mid-urethral sling [45]. 
UDS before bladder augmentation 
Ileocystoplasty and other methods of bladder aug-
mentation are highly invasive surgical procedures, with 
significant risk of severe complications. Their applicability 
in the therapy of idiopathic OAB remains marginal and is 
limited to extreme cases of low volume and low compli-
ance of the bladder. Due to the risk of severe surgical 
complications associated with opening of the gastroin-
testinal tract and integrating the intestinal mucosa into 
the urinary tract, bladder augmentation is not the method 
of choice for therapy resistant OAB, despite most satis-
factory functional results [46, 47]. Urodynamic testing is 
a vital component of the eligibility process for this form 
of treatment due to the need to confirm severe bladder 
dysfunction. 
UDS in patients with bladder outlet obstruction 
and voiding dysfunction
The prevalence of voiding dysfunction among women 
has been estimated at approximately 5%, but even in that 
group voiding dysfunction as the dominant symptom is re-
ported only by a small number of patients. Among patients 
who underwent UDS, the prevalence of impaired bladder 
emptying has been estimated at 6–30%, depending on the 
criteria. Numerous studies demonstrated bladder outlet 
obstruction to be an additional or unexpected urodynamic 
symptom in women undergoing UDS for reasons other 
than voiding dysfunction [2, 48, 49]. There are no strict in-
dications for urodynamic testing in the event of obstructive 
symptoms. The authors of this Guideline advise to take the 
post-void residual volume of > 100 mL in several measure-
ments or maximum flow rate in non-invasive uroflowme-
try < 15 mL/s as an indicator of voiding dysfunction. If the 
cause of the obstruction remains unclear after the physical 
and the ultrasound tests, UDS may be helpful in confirming 
or excluding bladder obstruction or detrusor underactivity. 
Still, urodynamic testing does not allow to determine the 
cause of the obstruction [2, 50, 51]. 
Detrusor underactivity is defined as the contraction of 
reduced strength and/or duration, resulting in prolonged 
bladder emptying or failure to achieve complete bladder 
emptying. Like bladder outlet obstruction, the diagnosis of 
detrusor underactivity in women has not yet been stand-
ardized. 
The following are used in the diagnostic process of de-
trusor underactivity: 
a) video-urodynamic test,
b) pressure-flow test, 
c) uroflowmetry,
d) stop-test (a modification of the pressure-flow test used 
to evaluate detrusor strain during isovolumetric contrac-
tion, i.e., during urethral closure achieved by catheter or 
sphincter contraction), 
e) voiding test with continuous urethral occlusion, 
f ) the PIP (1) parameter [projected isovolumetric pressure, 
PIP (1) = p det (Qmax) + Qmax], 
g) extremely low detrusor pressure (e.g., < 10 cm H2O) co-
existing with extremely low urinary flow rate [2, 50–52]. 
Urodynamic diagnosis of bladder outlet obstruction 
and detrusor underactivity in women is objective to some 
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extent, but it also depends on the physician who interprets 
the results, especially in borderline cases. Therefore, it is 
essential to analyze urodynamic results together with the 
physical examination and imaging test results [2, 53].
cONclUSIONS
Urodynamic testing is an essential element of urogy-
necological diagnostic process. The indications for UDS as 
well as the scope of testing are tailored to the needs of each 
patient. They result from the knowledge and experience of 
the physician, patient symptoms and indications, additional 
test results, current guidelines, as well as formal and legal 
requirements. 
The Polish Society of Gynecologists and Obstetricians 
issued this Guideline for the therapeutic options, with em-
phasis on the need for an individualized approach to uro-
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